Trent R. Hummel, MD, completed his graduate medical training at the University of Cincinnati College of Medicine, residency training in pediatrics at Children's Hospital Medical Center of Akron and pediatric hematology/oncology training at Cincinnati Children's Hospital Medical Center. His current appointment is at Cincinnati Children's Hospital Medical Center within the University of Cincinnati in the capacity of associate professor of pediatrics.
Dr. Hummel's clinical and academic interests pertain to children and families affected by central nervous system tumors. He is a member of the Central Nervous System (Brain Tumor) Committee in the Children's Oncology Group (COG) as well as the Cincinnati Children's co-principal investigator for the Pediatric Brain Tumor Consortium (PBTC). Dr. Hummel focuses on developing novel therapeutics to treat children with all central nervous system tumors including those patients with neurofibromatosis type 1 and 2 related CNS tumors and very poor prognosis tumors such as high-grade gliomas and diffuse intrinsic pontine gliomas.
BS: Eastern Mennonite University, Harrisburg, VA, 1997.
MD: University of Cincinnati College of Medicine, Cincinnati, OH, 2001.
Residency: Children’s Hospital Medical Center of Akron, Akron, OH, 2004.
Fellowship: Pediatric Hematology / Oncology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2007; Research Fellow, Division of Experimental Hematology, Cincinnati Children’s Hospital Medical Center, 2008.
Certification: American Board of Pediatrics, 2004; Pediatrics, 2004; Pediatric Hematology / Oncology, 2011.
Cancer and Blood Diseases, Brain Tumor, Neurofibromatosis, Rasopathy
Oncology, Cancer and Blood Diseases
Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.
Volumetric endpoints in diffuse intrinsic pontine glioma: comparison to cross-sectional measures and outcome correlations in the International DIPG/DMG Registry. Neuro-Oncology. 2022; 24:1598-1608.
Phase I study of ribociclib and everolimus in children with newly diagnosed DIPG and high-grade glioma: A CONNECT pediatric neuro-oncology consortium report. Neuro-Oncology Advances. 2022; 4.
Overcoming barriers to establishing autopsy procurement programs in pediatric patients with central nervous system tumors: a call to develop regional centers. Journal of Neuro-Oncology. 2021; 152:107-114.
Characterizing temporal genomic heterogeneity in pediatric low-grade gliomas. Acta neuropathologica communications. 2020; 8.
Visual field outcomes in children treated for neurofibromatosis type 1-associated optic pathway gliomas: a multicenter retrospective study. Journal of AAPOS. 2020; 24:349.e1-349.e5.
A phase I/II study of ribociclib following radiation therapy in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG). Journal of Neuro-Oncology. 2020; 149:511-522.
A Phase I and Pharmacokinetic Study of Oral Dabrafenib in Children and Adolescent Patients with Recurrent or Refractory BRAF V600 Mutation-Positive Solid Tumors. Clinical Cancer Research. 2019; 25:7294-7302.
Malignant peripheral nerve sheath tumor: Transformation in a patient with neurofibromatosis type 2. Pediatric Blood and Cancer. 2019; 66.
Pediatric intramedullary spinal cord tumor outcomes using the WeeFIM scale. Child's Nervous System. 2018; 34:1753-1758.
LGG-24. TEMPORAL GENOMIC HETEROGENEITY IN PEDIATRIC LOW-GRADE GLIOMAS. Neuro-Oncology. 2018; 20:i109-i109.
Patient Ratings and Comments
All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey